Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Lindsey Morrison

Nurse Practitioner Knightstown, IN Nurse Practitioner

NPI 1962831412 CMS profile 11239838

224 W Main St, Knightstown, IN 46148

Open in the dashboard

General payments

$11,798

826 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lindsey Morrison of Knightstown, IN is reported in the CMS Open Payments database as having received $11,798 across 826 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,852 110
2024 General $2,414 159
2023 General $2,765 194
2022 General $2,529 187
2021 General $2,237 176

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lindsey Morrison
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Lindsey Morrison were reported at $1,852. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Lindsey Morrison Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $2,237 $135 $40–$426 $132
2022 $2,529 $152 $48–$470 $149
2023 $2,765 $166 $54–$529 $160
2024 $2,414 $173 $55–$556 $164
2025 $1,852 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,709 146 payments
  2. Amgen Inc. $981 92 payments
  3. AstraZeneca Pharmaceuticals LP $758 20 payments
  4. Otsuka America Pharmaceutical, Inc. $621 36 payments
  5. GlaxoSmithKline, LLC. $616 37 payments
  6. Novo Nordisk Inc $595 52 payments
  7. Merck Sharp & Dohme Corporation $582 35 payments
  8. Lundbeck LLC $574 40 payments
  9. Pfizer Inc. $434 34 payments
  10. Novartis Pharmaceuticals Corporation $387 39 payments
  11. Other $4,542 295 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,713 825 payments
  2. Education $85 1 payment
Products named General payments · program years 2021–2025
  1. VERQUVO $776 45 payments
  2. FARXIGA $670 14 payments
  3. UBRELVY $652 50 payments
  4. REXULTI $621 36 payments
  5. Ozempic $569 50 payments
  6. VRAYLAR $565 53 payments
  7. BREZTRI $558 6 payments
  8. TRELEGY ELLIPTA $506 32 payments
  9. FASENRA $500 4 payments
  10. EVENITY $459 40 payments
  11. Other $11,131 825 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 185 drugs

Part D claims

9,846

Median for Nurse Practitioner: 389

Drug cost

$1,184,325

Median for Nurse Practitioner: $21,885

Branded share of claims

30.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 128 $92,294
Mounjaro Tirzepatide Brand 67 $89,376
Farxiga Dapagliflozin Propanediol Brand 79 $64,647
Vraylar Cariprazine Hcl Brand 40 $64,141
Rexulti Brexpiprazole Brand 42 $64,008
Linzess Linaclotide Brand 92 $61,187
Eliquis Apixaban Brand 80 $60,771
Jardiance Empagliflozin Brand 54 $54,378
Rybelsus Semaglutide Brand 37 $52,493
Repatha Sureclick Evolocumab Brand 67 $46,979

The 10 drugs with the highest cost, of 185 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$36,232

Of which drugs: $93

Medicare patients

150

Average age 67

Services billed

797

88 women, 62 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Diabetes 35%
Depression 33%
Ischemic heart disease 23%
Chronic kidney disease 23%
COPD 22%
Heart failure 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, ceftriaxone sodium, per 250 mg J0696 Office 23 104 $32
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 14 112 $8

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 42 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
$208 — —
REXULTI
$197 42 —
VERQUVO
$193 — —
QULIPTA
$121 — —
CAPLYTA
$113 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 42 with Patron

Records

826 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record